Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Nuscale Power Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Nuscale Power Corporation trades at $8.89 (market cap $3.13B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.7× Nuscale Power Corporation's market cap, and Alnylam Pharmaceuticals, Inc. is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| ALNY | SMR | |
|---|---|---|
Market Cap | $39.89B | $3.13B |
Sector | Health | Utilities |
52-Week High | $491.22 | $53.43 |
52-Week Low | $278.09 | $8.76 |
Enterprise Value | $38.15B | $2.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NuScale Power (SMR) trades at $9.03, showing no daily change. The stock exhibits a bearish technical trend with significant negative profitability metrics, including a net income margin of -2,066.55% and consecutive quarterly earnings misses. Despite these challenges, analyst consensus remains optimistic with a $13.00 price target, citing the company's first-mover advantage in small modular nuclear reactors and potential long-term growth tied to AI-driven power demand.
The outlook for SMR balances high-risk, high-reward potential. Opportunities include certified SMR technology and strategic partnerships, but risks are substantial: persistent operating losses, negative cash flow from operations, and uncertainty around commercial reactor sales. Investors face volatility with the stock near 52-week lows, requiring careful assessment of execution capability versus speculative growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
